Sterling Investment Advisors Ltd. Sells 280 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sterling Investment Advisors Ltd. reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,047 shares of the biopharmaceutical company’s stock after selling 280 shares during the quarter. Sterling Investment Advisors Ltd.’s holdings in Regeneron Pharmaceuticals were worth $3,203,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in REGN. J.W. Cole Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 11.5% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 802 shares of the biopharmaceutical company’s stock valued at $843,000 after buying an additional 83 shares during the last quarter. Frank Rimerman Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.5% in the third quarter. Frank Rimerman Advisors LLC now owns 597 shares of the biopharmaceutical company’s stock valued at $628,000 after acquiring an additional 20 shares during the period. Clear Harbor Asset Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 0.9% in the third quarter. Clear Harbor Asset Management LLC now owns 2,415 shares of the biopharmaceutical company’s stock worth $2,539,000 after acquiring an additional 21 shares during the last quarter. NorthCrest Asset Manangement LLC increased its position in Regeneron Pharmaceuticals by 2.5% during the third quarter. NorthCrest Asset Manangement LLC now owns 11,076 shares of the biopharmaceutical company’s stock worth $11,644,000 after acquiring an additional 271 shares during the period. Finally, Forsta AP Fonden raised its stake in Regeneron Pharmaceuticals by 9.9% during the 3rd quarter. Forsta AP Fonden now owns 24,500 shares of the biopharmaceutical company’s stock valued at $25,755,000 after purchasing an additional 2,200 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on REGN shares. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday. TD Cowen boosted their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,101.00.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $4.12 during midday trading on Friday, reaching $933.02. 547,777 shares of the company’s stock traded hands, compared to its average volume of 504,705. The company has a 50-day simple moving average of $1,088.44 and a two-hundred day simple moving average of $1,040.53. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The company has a market cap of $102.86 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 3.29 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period last year, the company posted $8.79 earnings per share. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.66 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.